Polynucleotide Ligase Activity of Eukaryotic Topoisomerase I
نویسندگان
چکیده
منابع مشابه
Induced Polynucleotide Kinase, Polynucleotide Ligase, and Deoxyribonucleic Acid Polymeraset
The mechanism of action of T4-induced polynu-cleotide kinase on short single-stranded deoxyoligonucleotideshas been investigated.It was found that the phosphorylationreaction catalyzed by T, polynucleotide kinase could be re-versed. Thus, a 5 ’-3*P-labeleddeoxyoligonucleotide and ADPon incubation with the enzyme formed [Y-~~PJATP.In addi-tion some radioac...
متن کاملEukaryotic DNA topoisomerase I reaction is topology dependent.
The effects of supercoiling on the topoisomerization reaction by eukaryotic DNA topoisomerases I have been analyzed. The systems used were: DNA topoisomerase I from wheat germ, chicken erythrocyte and calf thymus on a 2.3 kb DNA fragment which encompasses the immunoglobulin kappa-light chain (L kappa) promoter of the mouse plasmacytoma MPC11; S. cerevisiae DNA topoisomerase I on a 2.2 kb DNA fr...
متن کاملEukaryotic topoisomerase I-DNA interaction is stabilized by helix curvature.
The influence of DNA structure on topoisomerase I-DNA interaction has been investigated using a high affinity binding site and mutant derivatives thereof. Parallel determinations of complex formation and helix structure in the absence of superhelical stress suggest that the interaction is intensified by stable helix curvature. Previous work showed that a topoisomerase I binding site consists of...
متن کاملPolynucleotide ligase in bacteriophage T4D recombination.
Following infection of E. coli B with ligase-deficient rII bacteriophage T4D recombination between linked markers is increased 4.2 fold and heterozygote frequency increased 2.3 fold. In such infection recombination occurs at a rapid rate for an extended period. This is in contrast to the time course of recombination observed in wild-type, lysis-inhibited, or lysis-defective (gene t defective) i...
متن کاملMutagenic activity of topoisomerase I inhibitors
Topoisomerase I-directed agents are now in Phase I and II clinical trials and show great promise as potentially important agents for cancer chemotherapy. Because of their mechanism of action they may also be potential mutagens; however, their mutagenicity and oncogenicity still remain to be elucidated. We have previously shown that VP-16, a topoisomerase II-directed agent, induces sister chroma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cell
سال: 1998
ISSN: 1097-2765
DOI: 10.1016/s1097-2765(00)80073-8